<DOC>
	<DOCNO>NCT00443651</DOCNO>
	<brief_summary>This Phase III , open-label study total approximately 560 subject active rheumatoid arthritis ( RA ) inadequate response one disease-modifying anti-rheumatic drug ( DMARDs ) . Enrollment study conduct two stage . In Stage I study , approximately 400 subject receive non-biological DMARDs ( exception methotrexate [ MTX ] monotherapy MTX leflunomide combination therapy ) enrol . In Stage II study , approximately 160 subject receive Federal Drug Administration-approved biological DMARD time screen enrol .</brief_summary>
	<brief_title>A Study Safety Rituximab Combination With Other Anti-Rheumatic Drugs Subjects With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>Inclusion Criteria ( Stage I ) : Male female subject , 18 80 year age , document diagnosis active rheumatoid arthritis ( RA ) ≥ 6 month Receiving treatment RA outpatient basis Have inadequate response least one nonbiological diseasemodifying antirheumatic drug ( DMARD ) receive DMARD ( ) ≥ 12 week prior baseline , stable dose great equal 4 week prior baseline Demonstrated tolerability currently prescribe DMARDs If take background corticosteroid , use corticosteroid must stable dose 4 week prior first day treatment rituximab ( Day 1 ) Use one nonsteroidal antiinflammatory drug ( NSAID ) permit dose stable ≥ 2 week prior Day 1 Exclusion Criteria ( Stage I ) : Rheumatic autoimmune disease RA significant systemic involvement secondary RA ( include limit vasculitis , pulmonary fibrosis , Felty 's syndrome ) Functional Class IV define American College Rheumatology ( ACR ) Classification Functional Status Rheumatoid Arthritis History current inflammatory joint disease RA systemic autoimmune disorder Diagnosis juvenile idiopathic arthritis , juvenile RA , and/or RA age 16 year Any surgical procedure , include bone/joint surgery/synovectomy ( include joint fusion replacement ) within 12 week prior baseline plan within 24 week enrollment Lack peripheral venous access Significant cardiac pulmonary disease ( include obstructive pulmonary disease ) Evidence significant uncontrolled concomitant disease , limited , nervous system , renal , hepatic , endocrine , gastrointestinal disorder , investigator 's opinion , would preclude subject participation Primary secondary immunodeficiency ( history currently active ) , include know history human immunodeficiency virus ( HIV ) infection Known active infection kind ( exclude fungal infection nail bed ) , major episode infection require hospitalization treatment intravenous ( IV ) antibiotic within 4 week baseline completion oral antibiotic within 2 week prior baseline History medically significant opportunistic infection History serious recurrent chronic infection History deep space/tissue infection within 52 week prior baseline History cancer , include solid tumor , hematologic malignancy , carcinoma situ ( except basal cell squamous cell carcinoma skin excise cure ) History significant cytopenia bone marrow disorder History alcohol , drug , chemical abuse within 24 week prior baseline Pregnancy lactation Neuropathies neurovasculopathies might interfere pain evaluation Methotrexate ( MTX ) monotherapy time screen Concurrent treatment MTX leflunomide combination Concurrent treatment biologic agent Prior Day 1 , subject discontinue DMARDs/combinations prohibit protocol History severe allergic anaphylactic reaction biologic agent , know hypersensitivity component rituximab murine proteins Previous treatment antiα4 integrin agent Previous treatment celldepleting therapy , include investigational agent Receipt vaccine within 28 day prior baseline Intolerance contraindication IV corticosteroid Receipt IV immunoglobulin ( IVIG ) Prosorba &lt; TM &gt; column within 6 month prior baseline Any previous treatment rituximab Positive hepatitis B surface antigen , hepatitis B core antibody , hepatitis C antibody Inclusion Criteria ( Stage II ) : Male female subject , 18 80 year age , document diagnosis active RA ≥ 6 month , diagnose accord revised 1987 ACR criterion classification RA Receiving treatment RA outpatient basis Have inadequate response least one biologic DMARD receiving agent screen ≥ 12 week prior baseline , stable dose great equal 4 week prior baseline Have demonstrate tolerability currently prescribe DMARDs/biologics If take background corticosteroid , use corticosteroid must stable dose 4 week prior baseline Use one NSAID permit dose stable ≥ 2 week prior baseline Exclusion Criteria ( Stage II ) : Rheumatic autoimmune disease RA , significant systemic involvement secondary RA ( include limit vasculitis , pulmonary fibrosis , Felty 's syndrome ) Functional Class IV define ACR Classification Functional Status Rheumatoid Arthritis History , current , inflammatory joint disease RA systemic autoimmune disorder Diagnosis juvenile idiopathic arthritis , juvenile RA , and/or RA age 16 year Any surgical procedure , include bone/joint surgery/synovectomy ( include joint fusion replacement ) within 12 week prior baseline plan within 24 week randomization Lack peripheral venous access Significant cardiac pulmonary disease ( include obstructive pulmonary disease ) Evidence significant uncontrolled concomitant disease , limited , nervous system , renal , hepatic , endocrine gastrointestinal disorder , investigator 's opinion , would preclude subject participation Primary secondary immunodeficiency ( history currently active ) , include know history HIV infection Known active infection kind ( exclude fungal infection nail bed ) , major episode infection require hospitalization treatment IV antibiotic within 4 week baseline completion oral antibiotic within 2 week prior baseline History medically significant opportunistic infection History serious recurrent chronic infection History deep space/tissue infection within 52 week prior baseline History cancer , include solid tumor , hematologic malignancy , carcinoma situ ( except basal cell squamous cell carcinoma skin excise cure ) History significant cytopenia bone marrow disorder History alcohol , drug , chemical abuse within 24 week prior baseline Pregnancy lactation Neuropathies neurovasculopathies might interfere pain evaluation Infliximab monotherapy time screen ( infliximab combination MTX ) Concurrent treatment MTX leflunomide combination Concurrent treatment one biologic agent Prior Day 1 , subject discontinue DMARDs/combinations prohibit protocol History severe allergic anaphylactic reaction biologic agent , know hypersensitivity component rituximab murine proteins Previous treatment antiα4 integrin agent Previous treatment celldepleting therapy Treatment investigational agent within 28 day baseline 5 halflives investigational drug ( whichever longer ) Receipt vaccine within 28 day prior baseline Intolerance contraindication IV corticosteroid Receipt IVIG Prosorba &lt; TM &gt; column within 6 month prior baseline Any previous treatment rituximab Positive hepatitis B surface antigen , hepatitis B core antibody , hepatitis C antibody Positive purify protein derivative ( PPD ) skin test adequately treat accord Center Disease Control ( CDC ) guideline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Rituxan</keyword>
	<keyword>RA</keyword>
	<keyword>DMARD</keyword>
	<keyword>Active Rheumatoid Arthritis</keyword>
</DOC>